Opendata, web and dolomites

Capsulight

The first ingestible capsule for eradicating Helicobacter pylori infection through photodynamic therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Capsulight project word cloud

Explore the words cloud of the Capsulight project. It provides you a very rough idea of what is the project "Capsulight" about.

pump    hospitalization    validation    endoscopic    eradicated    gastroenterology    cured    spin    healthcare    cycles    90    optimize    ce    carcinogen    vitro    population    reducing    photobiology    infection    safety    proton    unparalleled    patented    helicobacter    photodynamic    centers    agent    undergo    50    medicine    antibiotic    capsulight    bacterium    usually    therapies    ingestible    once    preliminary    rate    drug    biopsy    therapy    tests    possibility    infected    cancers    presented    miniaturization    sant    florence    eradicate    diagnostic    despite    savings    70    inhibitor    biopsies    specialized    reaching    drugs    robotics    mix    market    light    probiomedica    diagnosed    national    capsules    clinical    97    posology    efficacy    attributable    university    killing    economic    power    advantages    capsule    pharmacological    resistance    gastric    assumption    anna    treatment    countries    mass    intragastric    showed    world    first    superiore    microbiology    secondary    mark    30    pylori    stomach    off    unfortunately    scuola    device   

Project "Capsulight" data sheet

The following table provides information about the project.

Coordinator
PROBIOMEDICA SRL 

Organization address
address: VIA DI BELLOSGUARDO 2 ROSSO
city: FIRENZE
postcode: 50124
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://www.probiomedica.it
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROBIOMEDICA SRL IT (FIRENZE) coordinator 50˙000.00

Map

 Project objective

Helicobacter pylori (H. pylori) is a bacterium of the stomach which affects on average 50% of the world population, reaching up to 70% in some European Countries. Once it is diagnosed, it has to be eradicated, since it is a carcinogen agent and around 90% of all gastric cancers can be attributable to its infection. The only available treatment is a pharmacological therapy based on the assumption of proton-pump inhibitor and a mix of 2-3 antibiotic drugs. Unfortunately, due to increasing antibiotic resistance, up to 30% of the affected population cannot be cured, despite several cycles of antibiotic therapy and usually endoscopic biopsy to determine antibiotic-resistance. Probiomedica is a spin-off of the University of Florence and Scuola Superiore Sant’Anna specialized in photobiology and robotics applied to medicine, which has developed and patented CapsuLight, the first ingestible capsule able to eradicate H. Pylori infection through intragastric photodynamic therapy, that is through the power of light. The device is based on the established technology and safety of endoscopic capsules for diagnostic use, and our preliminary in vitro tests showed 97% efficacy in killing the bacterium. The advantages for infected population are unparalleled: the possibility to eradicate the bacterium for those who cannot be cured due to antibiotic resistance (our first target market); the higher efficacy rate, no side effects due to antibiotic cycles, and easy posology for all the infected population (secondary market). CapsuLight will also provide high economic savings to National Healthcare Systems, by reducing drug therapies cycles and endoscopic biopsies and related costs for hospitalization. Probiomedica has already presented the product to several gastroenterology and microbiology centers and will optimize the capsule design for further miniaturization and mass production, and to undergo the necessary clinical validation for getting the CE mark during the Phase 2 project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAPSULIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAPSULIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More